Register Now
Youtube Linkedin Facebook

Private Equity Breakfast

Wednesday, July 26th | 8:30 a.m. - 9:30 a.m.
in the heart of the ADLM

Powered by:

Brown Gibbons Lang & Company LLC

DxPx US 2023: 3 Days In-Person + 2 Weeks of Digital Partnering

July 25 – 27, 2023 in Anaheim, CA

Only 15 Health Tech Company Spots
Apply Now!

We will be reaching out to applicants shortly to provide updates on their acceptance status for the Private Equity Breakfast.

Registration is FREE but highly exclusive: limited to 15 spots!

By applying, you consent to subscribing to the DxPx Newsletter and receiving marketing emails about upcoming DxPx Conferences and our in-house pitch competition, 42PLUS1.
dxpx usa breakfast

Enjoy the recognition of an established company + all the financial benefits of a startup.

You might be a small- or mid-cap company, but you’re on your way to becoming one of the next leaders in the industry. 

Meet the set of investors most appropriate for your advanced stage of growth while still enjoying the reduced ticket cost of a Startup company; we make it easy for you to attend DxPx.  

Unique opportunity for growth-stage & middle market Healthtech & Medtech players:

At DxPx US we host a dedicated breakfast for growth-stage and middle market companies and private equity groups. 

The number of participants is limited and participating companies are hand-selected by leading investors and business experts.

Private equity & growth company partnering breakfast
Private equity & growth company partnering breakfast

Benefits of the Private Equity Breakfast include:

  • Free participation, if selected
  • Small and exclusive event size, to ensure quality networking
  • Meet with at least 15 private equity groups
  • Follow-up discussions possible in private meeting areas
  • Eligibility to exhibit at a DxPx community booth

At DxPx we will also host two dedicated panel discussions on PE topics:

dxpx usa breakfast

You are grown but we still offer you startup benefits.

„At DxPx US only”

You’re are a small- & midcap company with at least 1 Mio. US revenues – and on your way to become one of the new industry leaders? We make it easy for you and still grant you reduced startup tickets to attend DxPx.

Private equity & growth company partnering breakfast

At DxPx US we host a dedicated breakfast to feature a limited number of pre-selected growth companies to private equity funds. We strive for a one-to-one ratio of executives and investors. Number of participants is limited and participating growth companies are selected by leading investors and business experts.

Private equity & growth company partnering breakfast

Explore the complete agenda:

Visit the Program Page
DxPx US 2023
Contact us for more information

Don't miss our investor conferences & early-stage investing events:

dxpx us adlm logos
DxPx US

DxPx Industry & Investor Conference US:
4 Days In-Person

July 29 - Aug. 1, 2024
Chicago, IL
In the ADLM

Stay up to date and sign up for our latest news:

Next: DxPx U.S. 2025
  • 3 Days In-Person
  • July 29 - 31, 2025
  • McCormick Place
    Convention Center
    Chicago, Illinois, USA
Next: DxPx EU 2026
  • 2 Days In-Person
  • Reception: February 5, 2026
    Partnering Day & 42PLUS1:
    February 6, 2026
  • Munich, Germany
Download Brochure
DxPx media
Useful links

© Copyright DxPx 2025. All Rights Reserved.

Youtube Linkedin Facebook

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.

Experience

Christoph Brandenberger

Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.

Experience

John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.

Experience

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.

Experience

FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Experience